摘要
目的：研究西洛他唑联合温经通络方对动脉硬化性闭塞症（ASO）患者临床症状及血流动力学的影响。方法：选取2016年9月一2017年9月期间医院收治的86例ASO患者作为研究对象，将所有患者随机分为两组：其中观察组43例（西洛他唑联合温经通络方外洗），对照组43例（西洛他唑），比较两组患者的临床疗效及学流动流血指标变化。结果：观察组治疗有效率88．37％（38／43），对照组72．09％（29／43），差异具有统计学意义（P〈0．05）。与治疗前相比，观察组胫后动脉及足背动脉内径明显增加（P〈0．05），血流速度明显减慢（P〈0．05）；对照组动脉内径无明显变化（P〉0．05），血流速度明显减慢（P〈0．05）。两组患者治疗后上述指标的差异具有统计学意义（P〈0．05）。结论：温经通络方联合西洛他唑能明显改善ASO患者的临床症状及血流动力学。
Objective： To study the influence of warming and activating meridian combined with cilostazol on symptoms and hemodynamics in ASO patients. Methods ： From September 2016 to September 2017, 86 patients were chosen as study objects, and all of them were divided into two groups randomly： 43 patientin study group （warming and activating meridian combined with cilostazol） and 43 patients in control group（cilostazol）. The effect rate and hemodynamic inde- xes were compared between two groups. Results： In study group, the effect rate was 88.37% （38/43） and that in control group was 72.09% （29/43）. The difference demonstrated statistical significance （ P 〈 0.05 ）. Compared with that before treatment, the diametersof the posterior tibial artery and dorsalis pedis artery increased significantly in the observation group（P 〈0. 05 ）, and the blood flow velocity slowed down significantly（P 〈0. 05 ）. There was no significant change in the arterial diameters of the control group （P 〉 0. 05 ）, and the blood flow velocity slowed down significantly （P 〈 0. 05 ）. The difference demonstrated the statistical significance （ P 〈 0. 05 ）. Conclusion ： Warming and activating meridian com- bined with cilostazol could alleviate the symptoms and hemodynamic disorder of ASO patients.
作者
孟路阳
俞雷来
田坤
MENG Luyang;YU Leilai;TIAN Kun(Department of Vascular Surgery,Hangzhou Third People＇ s Hospital,Hangzhou 310009,Zhejiang,China;Surgery of TraditionalChinese Medicine Hospital in Shengzhou,Shengzhou 312400,Zhejiang,China)
出处
《中华中医药学刊》
CAS
北大核心
2018年第8期2019-2022,共4页
Chinese Archives of Traditional Chinese Medicine
基金
杭州市科技发展计划项目(20160533B26)
关键词
温经通络方
西洛他唑
动脉硬化性闭塞症(ASO)
warming and activating meridian formula
cilostazol
arteriosclerosis obliterans（ASO）
